NR0B1

Nuclear receptor subfamily 0 group B member 1 · P51843 · NR0B1 on Sugi Atlas →

6,490 patent compounds predicted against NR0B1, 5,513 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Podofilox (SCHEMBL957281)	0.55	2/20
Vincristine (SCHEMBL3710)	1.00	1/20
Vincristine (SCHEMBL3998)	1.00	1/20
Colforsin (SCHEMBL4928)	1.00	1/20
Vorinostat (SCHEMBL9018)	1.00	1/20
Centaureidin (SCHEMBL9953)	1.00	1/20
Brefeldin A (SCHEMBL29267)	1.00	1/20
Brefeldin A (SCHEMBL29268)	1.00	1/20
Cytochalasin D (SCHEMBL33528)	1.00	1/20
Cytochalasin D (SCHEMBL33529)	1.00	1/20
Podofilox (SCHEMBL42243)	1.00	1/20
Axl-1717 (SCHEMBL159598)	1.00	1/20
Podofilox (SCHEMBL159599)	1.00	1/20
Podofilox (SCHEMBL255475)	1.00	1/20
SCHEMBL1401455	1.00	1/20
Colforsin (SCHEMBL1517319)	1.00	1/20
Axl-1717 (SCHEMBL1287609)	0.98	1/20
Vincristine (SCHEMBL3709)	0.97	1/20
Vincristine (SCHEMBL3999)	0.97	1/20
Vincristine (SCHEMBL233849)	0.97	1/20

Clinical trials — most relevant to NR0B1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Chronic Cold Acclimation Stimulates the Browning of Subcutaneous White Adipose in Patients With Type 2 Diabetes Mellitus	PHASE4	UNKNOWN
Fulvestrant in Metastatic Breast Cancer	PHASE4	UNKNOWN
Chronic Effects of Estrogen in Microcirculation	PHASE4	COMPLETED
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Preoperative Bexarotene Treatment for Cushing's Disease	PHASE1/PHASE2	UNKNOWN
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.	PHASE2	UNKNOWN
N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease	PHASE2	COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients	PHASE1/PHASE2	UNKNOWN
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
TNFSF11 Inhibition and Fertility: a Prospective Study	PHASE2	COMPLETED
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer	PHASE1/PHASE2	RECRUITING
AR-inhibitor Bicalutamide in Treating Patients With TNBC	PHASE2	UNKNOWN
Meclizine for Hepatocellular Carcinoma	PHASE1	COMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation?	nan	UNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone	nan	COMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
Immunolocalization of 1,25,Dihydroxyvitamin D3 in Aggressive Periodontitis Patients	nan	COMPLETED
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer	nan	UNKNOWN
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B.	nan	UNKNOWN
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions	nan	UNKNOWN
Studying Dexamethasone and Prednisone Sensitivity in Samples From Younger Patients With High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia	nan	COMPLETED
Comparison of Salivary Biormarkers Levels With Periodontal Clinical Parameters in Smokers and Non-Smokers With Different Periodontal Diseases	nan	COMPLETED
Replacement of Vitamin D in Patients With Active Tuberculosis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NR0B1 binder may also engage these)

Protein	Name	Similarity
Q9BG93	—	1.000	Q9BG93 →
Q9BG97	—	1.000	Q9BG97 →
Q9BG94	—	1.000	Q9BG94 →
Q9BG96	—	1.000	Q9BG96 →
P79386	—	1.000	P79386 →
P70503	—	0.995	P70503 →
Q61066	—	0.992	Q61066 →
Q9PU53	—	0.982	Q9PU53 →
Q80ZG2	—	0.981	Q80ZG2 →
Q8IWY8	—	0.981	Q8IWY8 →
Q4R8H9	—	0.980	Q4R8H9 →
A0A0J9YY54	—	0.980	A0A0J9YY54 →
Q9BXX2	—	0.979	Q9BXX2 →
Q14D33	—	0.979	Q14D33 →
Q6PCZ4	—	0.979	Q6PCZ4 →
Q9HCI5	—	0.979	Q9HCI5 →
Q9BE18	—	0.978	Q9BE18 →
Q8TD17	—	0.977	Q8TD17 →
Q8BGS3	—	0.976	Q8BGS3 →
Q5QGU6	—	0.976	Q5QGU6 →
Q9JI57	—	0.976	Q9JI57 →
Q9UDV7	—	0.976	Q9UDV7 →
Q5F378	—	0.976	Q5F378 →
Q9CWU5	—	0.976	Q9CWU5 →
Q96DU7	—	0.976	Q96DU7 →
Q5R741	—	0.976	Q5R741 →
F1LWT0	—	0.976	F1LWT0 →
Q9HB58	—	0.976	Q9HB58 →
A2T7D2	—	0.976	A2T7D2 →
A1A5P9	—	0.975	A1A5P9 →